Becton, Dickinson and Company vs Pfizer, Inc. — Stock Comparison
Becton, Dickinson and Company (BDX) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Becton, Dickinson and Company narrowly edges Pfizer, Inc. on Q·Score (6.4 vs 6.2 out of 10), led by Growth (6.2 vs 5.1) and Valuation (7.7 vs 7). Pfizer, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for BDX (+27.6%) than for PFE (+12.6%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $180.69 is 28% above current price.
⚠ analyst sentiment is cautious.
Consistently beats earnings estimates (4/4 quarters).
⚠ earnings contracting 10% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BDX vs PFE: which stock scores better overall?
Based on Q·Score, Becton, Dickinson and Company (BDX) scores 6.4/10 versus Pfizer, Inc. (PFE) at 6.2/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BDX or PFE?
Becton, Dickinson and Company (BDX) scores higher on Growth (6.2/10 vs 5.1/10). Becton, Dickinson and Company reports revenue growth (5.2% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BDX or PFE more attractively valued?
Becton, Dickinson and Company (BDX) scores higher on Valuation (7.7/10 vs 7/10). BDX trades at 10.6× P/E versus PFE at 9.2×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BDX vs PFE?
There are 13 analysts covering BDX with a consensus price target of $180.69, and 27 analysts covering PFE with a consensus target of $29.19. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BDX or PFE?
Becton, Dickinson and Company (BDX) scores higher on Quality (6.4/10 vs 6.4/10). Net profit margin: BDX at 5.1%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BDX or PFE?
Pfizer, Inc. (PFE) scores higher on Financial Health (7/10 vs 6.4/10). Market beta: BDX at 0.28, PFE at 0.29. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BDX and PFE?
Becton, Dickinson and Company (BDX) has a market capitalisation of $39.0B, while Pfizer, Inc. (PFE) has a market cap of $147.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BDX or PFE pay dividends?
BDX pays a dividend yield of 2.89%, while PFE pays a dividend yield of 6.61%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →